BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 25230908)

  • 1. The prognosis of MGMT promoter methylation in glioblastoma patients of different race: a meta-analysis.
    Yang H; Wei D; Yang K; Tang W; Luo Y; Zhang J
    Neurochem Res; 2014 Dec; 39(12):2277-87. PubMed ID: 25230908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognostic value of MGMT promoter methylation in Glioblastoma multiforme: a meta-analysis.
    Zhang K; Wang XQ; Zhou B; Zhang L
    Fam Cancer; 2013 Sep; 12(3):449-58. PubMed ID: 23397067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis of clinical trials.
    Binabaj MM; Bahrami A; ShahidSales S; Joodi M; Joudi Mashhad M; Hassanian SM; Anvari K; Avan A
    J Cell Physiol; 2018 Jan; 233(1):378-386. PubMed ID: 28266716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic value of MGMT promoter status by pyrosequencing assay for glioblastoma patients' survival: a meta-analysis.
    Zhao H; Wang S; Song C; Zha Y; Li L
    World J Surg Oncol; 2016 Oct; 14(1):261. PubMed ID: 27733166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MGMT promoter methylation status as a prognostic factor for the outcome of gamma knife radiosurgery for recurrent glioblastoma.
    Kim BS; Kong DS; Seol HJ; Nam DH; Lee JI
    J Neurooncol; 2017 Jul; 133(3):615-622. PubMed ID: 28536992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MGMT promoter methylation in patients with glioblastoma: is methylation-sensitive high-resolution melting superior to methylation-sensitive polymerase chain reaction assay?
    Yamashita S; Yokogami K; Matsumoto F; Saito K; Mizuguchi A; Ohta H; Takeshima H
    J Neurosurg; 2018 May; 130(3):780-788. PubMed ID: 29726772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased expression of the histone H3 lysine 4 methyltransferase MLL4 and the histone H3 lysine 27 demethylase UTX prolonging the overall survival of patients with glioblastoma and a methylated MGMT promoter.
    Kim J; Lee SH; Jang JH; Kim MS; Lee EH; Kim YZ
    J Neurosurg; 2017 May; 126(5):1461-1471. PubMed ID: 27367247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients.
    Cheng W; Ren X; Cai J; Zhang C; Li M; Wang K; Liu Y; Han S; Wu A
    Oncotarget; 2015 Oct; 6(30):29285-95. PubMed ID: 26320189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surgery for Glioblastoma in Light of Molecular Markers: Impact of Resection and MGMT Promoter Methylation in Newly Diagnosed IDH-1 Wild-Type Glioblastomas.
    Gessler F; Bernstock JD; Braczynski A; Lescher S; Baumgarten P; Harter PN; Mittelbronn M; Wu T; Seifert V; Senft C
    Neurosurgery; 2019 Jan; 84(1):190-197. PubMed ID: 29617848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MGMT inactivation and clinical response in newly diagnosed GBM patients treated with Gliadel.
    Grossman R; Burger P; Soudry E; Tyler B; Chaichana KL; Weingart J; Olivi A; Gallia GL; Sidransky D; Quiñones-Hinojosa A; Ye X; Brem H
    J Clin Neurosci; 2015 Dec; 22(12):1938-42. PubMed ID: 26249244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
    Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK
    Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome.
    Lalezari S; Chou AP; Tran A; Solis OE; Khanlou N; Chen W; Li S; Carrillo JA; Chowdhury R; Selfridge J; Sanchez DE; Wilson RW; Zurayk M; Lalezari J; Lou JJ; Ormiston L; Ancheta K; Hanna R; Miller P; Piccioni D; Ellingson BM; Buchanan C; Mischel PS; Nghiemphu PL; Green R; Wang HJ; Pope WB; Liau LM; Elashoff RM; Cloughesy TF; Yong WH; Lai A
    Neuro Oncol; 2013 Mar; 15(3):370-81. PubMed ID: 23328811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between O6-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide.
    Minniti G; Salvati M; Arcella A; Buttarelli F; D'Elia A; Lanzetta G; Esposito V; Scarpino S; Maurizi Enrici R; Giangaspero F
    J Neurooncol; 2011 Apr; 102(2):311-6. PubMed ID: 20686820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study.
    Kim YS; Kim SH; Cho J; Kim JW; Chang JH; Kim DS; Lee KS; Suh CO
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):661-7. PubMed ID: 22414280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic modulation of the drug resistance genes MGMT, ABCB1 and ABCG2 in glioblastoma multiforme.
    Oberstadt MC; Bien-Möller S; Weitmann K; Herzog S; Hentschel K; Rimmbach C; Vogelgesang S; Balz E; Fink M; Michael H; Zeden JP; Bruckmüller H; Werk AN; Cascorbi I; Hoffmann W; Rosskopf D; Schroeder HW; Kroemer HK
    BMC Cancer; 2013 Dec; 13():617. PubMed ID: 24380367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The utilization of MGMT promoter methylation testing in United States hospitals for glioblastoma and its impact on prognosis.
    Lee A; Youssef I; Osborn VW; Safdieh J; Becker DJ; Schreiber D
    J Clin Neurosci; 2018 May; 51():85-90. PubMed ID: 29483008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is MGMT promoter methylation to be considered in the decision making for recurrent surgery in glioblastoma patients?
    Pala A; Schmitz AL; Knoll A; Schneider M; Hlavac M; König R; Wirtz CR; Coburger J
    Clin Neurol Neurosurg; 2018 Apr; 167():6-10. PubMed ID: 29425743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.
    Li H; Li J; Cheng G; Zhang J; Li X
    Clin Neurol Neurosurg; 2016 Dec; 151():31-36. PubMed ID: 27764705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The predictive but not prognostic value of MGMT promoter methylation status in elderly glioblastoma patients: a meta-analysis.
    Yin AA; Zhang LH; Cheng JX; Dong Y; Liu BL; Han N; Zhang X
    PLoS One; 2014; 9(1):e85102. PubMed ID: 24454798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apparent diffusion coefficient obtained by magnetic resonance imaging as a prognostic marker in glioblastomas: correlation with MGMT promoter methylation status.
    Romano A; Calabria LF; Tavanti F; Minniti G; Rossi-Espagnet MC; Coppola V; Pugliese S; Guida D; Francione G; Colonnese C; Fantozzi LM; Bozzao A
    Eur Radiol; 2013 Feb; 23(2):513-20. PubMed ID: 22875158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.